Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel… Read more
Eusol Biotech Co.,Ltd. (6652) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.047x
Based on the latest financial reports, Eusol Biotech Co.,Ltd. (6652) has a cash flow conversion efficiency ratio of -0.047x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-16.49 Million) by net assets (NT$347.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eusol Biotech Co.,Ltd. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Eusol Biotech Co.,Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eusol Biotech Co.,Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eusol Biotech Co.,Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Impero AS
CO:IMPERO
|
-1.696x |
|
Soktas Tekstil Sanayi ve Ticaret AS
IS:SKTAS
|
-0.027x |
|
Amanah Leasing Public Company Limited
BK:AMANAH
|
0.038x |
|
TRP_AESTHETIC CONNECT
BK:TRP
|
0.005x |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
-0.041x |
|
Mercer Bancorp Inc.
OTCGREY:MSBB
|
0.070x |
|
JG Environmental Technology Co.,Ltd.
TWO:6723
|
0.171x |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
-0.075x |
Annual Cash Flow Conversion Efficiency for Eusol Biotech Co.,Ltd. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Eusol Biotech Co.,Ltd. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$370.43 Million | NT$-32.09 Million | -0.087x | +20.00% |
| 2023-12-31 | NT$400.98 Million | NT$-43.42 Million | -0.108x | +13.63% |
| 2022-12-31 | NT$421.82 Million | NT$-52.88 Million | -0.125x | +38.79% |
| 2021-12-31 | NT$434.03 Million | NT$-88.89 Million | -0.205x | +40.64% |
| 2020-12-31 | NT$260.75 Million | NT$-89.96 Million | -0.345x | -153619.91% |
| 2019-12-31 | NT$365.87 Million | NT$-82.11K | 0.000x | -- |